DXR · Daxor Corp · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-28 | Jefferies John |
Chief Medical Officer |
Award↑
Filing footnotes — Daxor Common Stock (Direct)
2,451 shares granted vest on August 28, 2026. |
Daxor Common Stock
|
2,451 |
| 2026-06-23 | DesRosiers Caleb |
Director |
Award↑
Filing footnotes — Stock options (right to buy) (Direct)
Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan") The stock options will vest in three (3) installments - June 23, 2026 (833); June 23, 2027 (833); June 23, 2028 (834) |
Stock options (right to buy)
|
2,500 |
| 2026-06-23 | Feldschuh Jonathan Adam |
Director, Chief Scientific Officer |
Award↑
Filing footnotes — Daxor Common Stock (Direct)
25,000 shares granted vest on June 23, 2026. |
Daxor Common Stock
|
25,000 |
| 2026-06-23 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Daxor Common Stock (Direct)
30,000 shares granted vest on June 23, 2026 |
Daxor Common Stock
|
30,000 |
| 2026-06-23 | Feuer Edward |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834) |
Stock Options (right to buy)
|
2,500 |
| 2026-06-23 | Cremisi Henry D. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834) |
Stock Options (right to buy)
|
2,500 |
| 2026-06-23 | Michel Robert J |
Director |
Award↑
Filing footnotes — Daxor Common Stock (Direct)
12,000 shares granted vest on June 23, 2026. |
Daxor Common Stock
|
12,000 |
| 2026-06-23 | Goudie Joy S. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834) |
Stock Options (right to buy)
|
2,500 |
| 2026-04-08 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
1,000 |
| 2026-03-31 | Michel Robert J |
Director |
Buy↑
|
Daxor Common Stock
|
1,000 |
| 2026-03-20 | Jefferies John |
Chief Medical Officer |
Buy↑
Filing footnotes — Daxor Common Stock (Direct)
3,656 shares granted vest on March 20, 2029. |
Daxor Common Stock
|
3,656 |
| 2026-03-20 | Jefferies John |
Chief Medical Officer |
Buy↑
Filing footnotes — Daxor Common Stock (Direct)
2,285 shares granted vested on March 20, 2026 |
Daxor Common Stock
|
2,285 |
| 2025-12-09 | Feldschuh Jonathan Adam |
Director, Chief Scientific Officer |
Buy↑
Filing footnotes — Daxor Common Stock (Direct)
18,000 shares granted vest on December 9, 2025. |
Daxor Common Stock
|
18,000 |
| 2025-12-09 | Michel Robert J |
Director |
Buy↑
Filing footnotes — Daxor Common Stock (Direct)
3,000 shares granted vest on December 9, 2025. |
Daxor Common Stock
|
3,000 |
| 2025-11-12 | Jefferies John |
Chief Medical Officer |
Buy↑
Filing footnotes — Daxor Common Stock (Direct)
2,344 shares granted vest on November 12, 2025. |
Daxor Common Stock
|
2,344 |
| 2025-06-24 | Goudie Joy S. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834) |
Stock Options (right to buy)
|
2,500 |
| 2025-06-24 | Feuer Edward |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834) |
Stock Options (right to buy)
|
2,500 |
| 2025-06-24 | Cremisi Henry D. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on June 24, 2025 (833), June 24, 2026 (883) and June 24, 2027 (834) |
Stock Options (right to buy)
|
2,500 |
| 2025-06-24 | DesRosiers Caleb |
Director |
Award↑
Filing footnotes — Stock options (right to buy) (Direct)
Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan") The stock options will vest in three (3) installments - June 24, 2025 (833); June 24, 2026 (833); June 24, 2027 (834) |
Stock options (right to buy)
|
2,500 |
| 2025-04-04 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
2,063 |
| 2025-03-10 | Michel Robert J |
Director |
Buy↑
|
Daxor Common Stock
|
1,000 |
| 2024-12-06 | Feldschuh Jonathan Adam |
Director, Chief Scientific Officer |
Buy↑
Filing footnotes — Daxor Common Stock (Direct)
32,000 shares granted vest on December 6, 2024. |
Daxor Common Stock
|
32,000 |
| 2024-12-06 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Daxor Common Stock (Direct)
45,000 shares granted vest on December 6, 2024 |
Daxor Common Stock
|
45,000 |
| 2024-07-15 | Goudie Joy S. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 15, 2024 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 15, 2024 (833), July 15, 2025 (883) and July 15, 2026 (834) |
Stock Options (right to buy)
|
2,500 |
| 2024-07-15 | DesRosiers Caleb |
Director |
Award↑
Filing footnotes — Stock options (right to buy) (Direct)
Stock options granted on July 11, 2022 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan") The stock options will vest in three (3) installments - July 15, 2024 (833); July 15, 2025 (833); July 15, 2026 (834) |
Stock options (right to buy)
|
2,500 |
| 2024-07-15 | Cremisi Henry D. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 15, 2024 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 15, 2024 (833), July 15, 2025 (883) and July 15, 2026 (834) |
Stock Options (right to buy)
|
2,500 |
| 2024-07-15 | Feuer Edward |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 15, 2024 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 15, 2024 (833), July 15, 2025 (883) and July 15, 2026 (834) |
Stock Options (right to buy)
|
2,500 |
| 2024-03-27 | Michel Robert J |
Director |
Buy↑
|
Daxor Common Stock
|
750 |
| 2024-03-26 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
1,000 |
| 2024-03-19 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
647 |
| 2024-03-10 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
1,492 |
| 2024-03-04 | Feuer Edward |
Director |
Buy↑
|
Daxor Common Stock
|
1,000 |
| 2023-12-06 | Michel Robert J |
Director |
Buy↑
|
Daxor Common Stock
|
120 |
| 2023-12-01 | Michel Robert J |
Director |
Buy↑
|
Daxor Common Stock
|
180 |
| 2023-12-01 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
800 |
| 2023-11-24 | Michel Robert J |
Director |
Buy↑
|
Daxor Common Stock
|
500 |
| 2023-11-21 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Award↑
|
Daxor Common Stock
|
84 |
| 2023-11-10 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
1,001 |
| 2023-11-09 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Buy↑
|
Daxor Common Stock
|
401 |
| 2023-10-31 | Michel Robert J |
Director |
Award↑
Filing footnotes — Daxor Common Stock (Direct)
Shares granted vest in three (3) equal installments. 666 vest on October 31, 2023; 666 will vest on October 31, 2024; and 668 will vest on October 31, 2025 |
Daxor Common Stock
|
2,000 |
| 2023-10-31 | Michel Robert J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on October 31, 2023 are contingent on certain regulatory approvals. The stock options will vest in three installments. 1,666 vest on October 31, 2023; 1,666 will vest October 31, 2024; and 1,668 will vest on October 31, 2026. |
Stock Options (right to buy)
|
5,000 |
| 2023-10-13 | Michel Robert J |
Director |
Buy↑
|
Daxor Common Stock
|
500 |
| 2023-09-18 | Estate of Joseph Feldschuh |
10% Owner |
Gift↓
|
Common Stock
|
25,000 |
| 2023-07-11 | Michel Robert J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 11, 2023 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 11, 2024 (4,666), July 11, 2025 (4,666) and July 11, 2026 (4,668) |
Stock Options (right to buy)
|
14,000 |
| 2023-07-11 | Goudie Joy S. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 11, 2023 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 11, 2024 (833), July 11, 2025 (883) and July 11, 2026 (834) |
Stock Options (right to buy)
|
2,500 |
| 2023-07-11 | Feldschuh Jonathan Adam |
Director, Chief Scientific Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 11, 2023 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 11, 2024 (8,333), July 11, 2025 (8,333) and July 11, 2026 (8,334) |
Stock Options (right to buy)
|
25,000 |
| 2023-07-11 | DesRosiers Caleb |
Director |
Award↑
Filing footnotes — Stock options (right to buy) (Direct)
Stock options granted on July 11, 2022 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan") The stock options will vest in three (3) installments - July 11, 2024 (833); July 11, 2025 (834); July 11, 2026 (666) |
Stock options (right to buy)
|
2,500 |
| 2023-07-11 | Cremisi Henry D. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 11, 2023 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 11, 2024 (833), July 11, 2025 (883) and July 11, 2026 (834) |
Stock Options (right to buy)
|
2,500 |
| 2023-07-11 | Feldschuh Michael Richard |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 11, 2023 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 11, 2024 (10,000), July 11, 2025 (10,000) and July 11, 2026 (10,000) |
Stock Options (right to buy)
|
30,000 |
| 2023-07-11 | LOMBARD JAMES A |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
Stock options granted on July 11, 2023 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan"). The stock options will vest in three installments on July 11, 2024 (833), July 11, 2025 (883) and July 11, 2026 (834) |
Stock Options (right to buy)
|
2,500 |